July 21, 2014 – Charleston, SC — Innocutis is pleased to announce the introduction into the North American markets of Sitavig® (ACYCLOVIR) 50mg Buccal Tablet. Sitavig (50mg acyclovir) Muco-Adhesive Buccal Tablet, represents a treatment breakthrough in the herpes...
July 21, 2014 – Charleston, SC — Innocutis is pleased to announce the introduction into the North American markets of Sitavig® (ACYCLOVIR) 50mg Buccal Tablet. Sitavig (50mg acyclovir) Muco-Adhesive Buccal Tablet, represents a treatment breakthrough in the herpes...
CHARLESTON, S.C., March 19, 2014 /PRNewswire/ – Innocutis Holdings LLC, an innovative pharmaceutical company dedicated to marketing best-in-class branded prescription products in skin-related therapies, is pleased to announce the licensing of Sitavig® (ACYCLOVIR) 50mg...
You are about to leave the Sitavig product website.
EPI Health does not administer the information on the linked website,
and does not monitor or endorse the information. This link solely provides additional information that may help you
locate and identify other Internet resources that may be of interest.
